A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

被引：58

作者：

Brodszky, Valentin ^{[1
]}

Rencz, Fanni ^{[1
,2
]}

Pentek, Marta ^{[1
]}

Baji, Petra ^{[1
]}

Lakatos, Peter L. ^{[3
]}

Gulacsi, Laszlo ^{[1
]}

机构：

[1] Corvinus Univ Budapest, Dept Hlth Econ, Fovam Ter 8, H-1093 Budapest, Hungary

[2] Semmelweis Univ, Doctoral Sch Clin Med, Ulloi Ut 26, H-1085 Budapest, Hungary

[3] Semmelweis Univ, Dept Med 1, Koranyi S 2-A, H-1083 Budapest, Hungary

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2016年 / 16卷 / 01期

关键词：

biosimilar drugs; budget impact analysis; Central and Eastern Europe; Crohn's disease; inflammatory bowel diseases; infliximab; INFLAMMATORY-BOWEL-DISEASE; BIOLOGICAL THERAPY; POSITION STATEMENT; MEDICINES; EFFICACY; SAFETY; CT-P13;

D O I：

10.1586/14737167.2015.1067142

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Objectives: To estimate the budget impact of the introduction of biosimilar infliximab for the treatment of Crohn's disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. Methods: A 3-year, prevalence-based budget impact analysis for biosimilar infliximab to treat CD was developed from third-party payers' perspective. The model included various scenarios depending on whether interchanging originator infliximab with biosimilar infliximab was allowed or not. Results: Total cost savings achieved in biosimilar scenario 1 (interchanging not allowed) and BSc2 (interchanging allowed in 80% of the patients) were estimated to Euro8.0 million and Euro16.9 million in the six countries. Budget savings may cover the biosimilar infliximab therapy for 722-1530 additional CD patients. Conclusions: Introduction of biosimilar infliximab to treat CD may offset the inequity in access to biological therapy for CD between Central and Eastern European countries.

引用

页码：119 / 125

页数：7

共 26 条

[1]

Bakhshai Justin, 2010, J Med Econ, V13, P63, DOI 10.3111/13696990903543424

[2] Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries [J].

Brodszky, Valentin ;

Baji, Petra ;

Balogh, Orsolya ;

Pentek, Marta .

EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 :S65-S71

[3] The burden of inflammatory bowel disease in Europe [J].

Burisch, Johan ;

Jess, Tine ;

Martinato, Matteo ;

Lakatos, Peter L. .

JOURNAL OF CROHNS & COLITIS, 2013, 7 (04) :322-337

[4] Epidemiology and Natural History of Inflammatory Bowel Diseases [J].

Cosnes, Jacques ;

Gower-Rousseau, Corinne ;

Seksik, Philippe ;

Cortot, Antoine .

GASTROENTEROLOGY, 2011, 140 (06) :1785-U118

[5] ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) [J].

Danese, Silvio ;

Gomollon, Fernando .

JOURNAL OF CROHNS & COLITIS, 2013, 7 (07) :586-589

[6]

Department of Medical Expertise Clinical Auditing and Analysis NHIFA, 2012, BIOL THER 2006 2010

[7] A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease [J].

Dretzke, J. ;

Edlin, R. ;

Round, J. ;

Connock, M. ;

Hulme, C. ;

Czeczot, J. ;

Fry-Smith, A. ;

McCabe, C. ;

Meads, C. .

HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (06) :1-+

[8]

Gecse K, 2015, J CROHNS COLITIS, V9, pS234

[9] HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain [J].

Gulacsi, L. ;

Pentek, M. .

EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (07) :675-680

[10] Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria [J].

Gulacsi, Laszlo ;

Rotar, Alexandru M. ;

Niewada, Maciej ;

Loeblova, Olga ;

Rencz, Fanni ;

Petrova, Guenka ;

Boncz, Imre ;

Klazinga, Niek S. .

EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 :S13-S25

← 1 2 3 →